This is the authors' abstract. We don't add key points for this paper.
Epidermal growth factor receptor inhibitors (EGFR) have a high rate of class-specific dermatologic adverse events. Supportive treatment of dermatologic adverse events decreases their severity, minimizes the need for dose de-escalation / discontinuation of targeted therapy, improves commitment to anticancer treatment and patient’s quality of life. Close interdisciplinary cooperation between oncologists and dermatologists is a key to the successful management of patients treated with EGFR. This article highlights current approaches to classification, concepts of pathogenesis and clinical course of EGFR-associated dermatologic adverse events, current and promising prophylactic and therapeutic strategies to manage these adverse events.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Polonskaia et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: